|
09 Oct 2019 |
Novartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mg
|
|
08 Oct 2019 |
ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy
|
|
08 Oct 2019 |
Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
|
|
07 Oct 2019 |
Janssen Submits Application to U.S. FDA Seeking Approval of STELARA® (ustekinumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
|
|
04 Oct 2019 |
New Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis
|
|
04 Oct 2019 |
I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5
|
|
04 Oct 2019 |
FASENRA (benralizumab) Approved in the US for Self-administration in a New Pre-filled Auto-injector, the FASENRA Pen™
|
|
03 Oct 2019 |
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
|
|
02 Oct 2019 |
Merck’s KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
|
|
02 Oct 2019 |
Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update
|
|
01 Oct 2019 |
OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor (BiCKI®) Platform Targeting PD-1 and Cytokines to Overcome Tumor Resistance to Checkpoint Inhibitor Blockade
|
|
01 Oct 2019 |
Checkpoint Therapeutics Announces Presentation of Positive Interim Clinical Results for Anti-PD-L1 Cosibelimab at the European Society for Medical Oncology (ESMO) Congress 2019
|
|
01 Oct 2019 |
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approves Label Update for Crysvita® (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH)
|
|
01 Oct 2019 |
AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis
|
|
01 Oct 2019 |
Innate Pharma presents early clinical data on IPH5401 and monalizumab at the ESMO 2019 congress
|
|
30 Sep 2019 |
Opdivo (nivolumab) Demonstrates Statistically Significant Overall Survival Benefit Versus Chemotherapy in Patients with Advanced Esophageal Cancer
|
|
30 Sep 2019 |
Genentech Presents Positive Phase III Results for Tecentriq (Atezolizumab) in Combination With Platinum-based Chemotherapy in People With Previously Untreated Advanced Bladder Cancer
|
|
30 Sep 2019 |
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)
|
|
30 Sep 2019 |
Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX005 in Guillain-Barré Syndrome
|
|
30 Sep 2019 |
Iksuda Therapeutics Presents First Data on Lead Antibody Drug Conjugate, Demonstrating Effective Tumour Regression
|
|
29 Sep 2019 |
Aravive Presents Positive Data from Initial 12 Patients in Phase 1b Portion of its Phase 1b/2 Ovarian Cancer Study of AVB-500 in Late Breaking Oral Presentation at European Society for Medical Oncology Congress in Barcelona
|
|
29 Sep 2019 |
GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC)
|
|
29 Sep 2019 |
Adjuvant Treatment with Opdivo (nivolumab) Continues to Demonstrate Extended Recurrence-Free Survival at Three Years in Resected High-Risk Melanoma Patients
|
|
29 Sep 2019 |
Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma
|
|
29 Sep 2019 |
ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin® at ESMO
|
